Analysis reveals clonal hematopoiesis affects relapse rates in lymphoma patients post-transplant, suggesting need for revised strategies.
Key Points
Patients with clonal hematopoiesis had higher relapse rates, particularly in lymphoma, indicating a significant impact on survival outcomes.
Among 142 patients treated, 14 of 31 AML, 13 of 64 myeloma, and 9 of 47 lymphoma patients exhibited gene mutations linked to clonal hematopoiesis.
The observational study evaluated the effects of high-dose chemotherapy and autologous stem cell transplantation across multiple hematological cancers.
Longer follow-ups and larger cohort studies are essential to conclusively verify the implications of clonal hematopoiesis on survival.